- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07460323
Studie av TRE-tätningar på tidiga postoperativa patienter
Studie av TRE-förseglingar på tidiga postoperativa patienter
This study will evaluate two Ostomy Seals/Rings in a group of post-operative patients.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: John Whitaker; Chief Investigator
- Telefonnummer: 27148 024 7696 7148
- E-post: John.Whitaker@uhcw.nhs.uk
Studieorter
-
-
County Durham
-
Stockton-on-Tees, County Durham, Storbritannien, TS19 8PE
- Rekrytering
- North Tees University Hospital
-
Kontakt:
- Abdalla Mustafa
- Telefonnummer: 7940211807
- E-post: abdallamustafa1@nhs.net
-
-
East Sussex
-
Saint Leonards-on-Sea, East Sussex, Storbritannien, TN37 7RD
- Rekrytering
- East Sussex Healthcare NHS Trust: Conquest and Eastbourne Hospitals
-
Kontakt:
- Janet Sinclair
- Telefonnummer: 7741408250
- E-post: janet.sinclair4@nhs.net
-
-
Kent
-
Ashford, Kent, Storbritannien, TN24 0LZ
- Rekrytering
- William Harvey Hospital
-
Kontakt:
- Lalmaya Pun
- Telefonnummer: 1233616646
- E-post: lalmaya.pun@nhs.net
-
Margate, Kent, Storbritannien, CT9 4AN
- Rekrytering
- Queen Elizabeth The Queen Mother Hospital
-
Kontakt:
- Susan Biles
- Telefonnummer: 1233616646
- E-post: susan.biles@nhs.net
-
-
North Yorkshire
-
Middlesbrough, North Yorkshire, Storbritannien, TS4 3BW
- Rekrytering
- South Tees University Hospital
-
Kontakt:
- Anil Reddy
- Telefonnummer: 01642 850850
- E-post: Anil.reddy@nhs.net
-
-
Surrey
-
Redhill, Surrey, Storbritannien, RH1 5RH
- Rekrytering
- East Surrey Hospital
-
Kontakt:
- Mathew Varghese
- Telefonnummer: 01737 231728
- E-post: mathew.varghese8@nhs.net
-
-
West Midlands
-
Coventry, West Midlands, Storbritannien, CV2 2DX
- Rekrytering
- University Hospital Coventry
-
Kontakt:
- Michelle Hicken
- Telefonnummer: 27148 024 7696 7148
- E-post: michelle.hicken@uhcw.nhs.uk
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- At least 18 years of age
- Has their ostomy surgery and post-operative care in the United Kingdom (UK)
- Has a colostomy, ileostomy, or urostomy and no reversal planned during the study evaluation period
- Able to have first study product applied at first pouch change after surgery (or up to 4 days post-op)
- Is appropriate to use a barrier seal per the Investigator
- Able to provide an informed consent for study participation
- Willing to follow protocol procedures, including participating in study visits, as demonstrated by signing the informed consent
Exclusion Criteria:
- Is over 85 years of age
- Has received chemotherapy or radiation in the past 30 days or reports beginning chemotherapy or radiation during the study.
- A score of 1, 2, or 3 for any of the three OCSI Tool PSC-related domains (i.e., peristomal irritant dermatitis, peristomal bleeding, and hyperplasia) at time of enrollment
- Has a fistula in the peristomal area at time of enrollment
- Has an open draining wound (not including mucocutaneous separation) in the peristomal area at time of enrollment
- Has a suspected infection in the peristomal area at time of enrollment
- Is pregnant or lactating at time of enrollment (as determined by interview only)
- Is unable to speak, read, and understand English.
- Is currently participating in another clinical study using ostomy products
- Is currently an employee of Hollister Incorporated or any ostomy manufacturer
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: En stomisegel
|
An absorptive ostomy seal |
|
Aktiv komparator: En stomiring
|
The Ostomy Ring contains Aloe |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The Risk of Peristomal Skin Complications (PSCs) as measured using the three PSC-related questions on the Ostomy Complication Severity Index (OCSI)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
The three PSC-related questions on the Ostomy Complication Severity Index (OCSI) are related to peristomal irritant dermatitis, peristomal bleeding, and hyperplasia. Each of these three items is rated on a scale of 0-3, with 0 indicating absence of the condition, and 3 indicating the condition is severe. |
From enrollment to the end of treatment at 9 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Total Ostomy Complication Severity Index (OCSI) score and six stomal complication (non-PSC) domains of the OCSI and associated severity
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Each of the OCSI items are scored on a scale of 0-3, with 0 indicating absence of the condition and 3 indicating the condition is severe. |
From enrollment to the end of treatment at 9 weeks
|
|
Mediation of peristomal skin complications (PSCs) by leakage absorption measured using the leakage item on the Ostomy Complication Severity Index (OCSI)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
The leakage item on the OCSI has a scale of 0 (no leakage) to 3 (leakage approximately 1-2 times per day) |
From enrollment to the end of treatment at 9 weeks
|
|
Visible moisture/effluent on peristomal skin under the study seal area (OCSI Supplementary Question)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Assessed only if leakage is reported in the OCSI tool (conditional). Responses: Great amount / Slight amount / None (ordinal categorical). |
From enrollment to the end of treatment at 9 weeks
|
|
Seal absorption of moisture/effluent under the study seal area (OCSI Supplementary Question)
Tidsram: From enrollment to end of treatment at 9 weeks
|
Participant response to whether the study seal absorbed moisture/effluent from around the stoma/peristomal skin under the seal. Responses: Yes / Somewhat / No, not at all (ordinal categorical). |
From enrollment to end of treatment at 9 weeks
|
|
Presence of peristomal skin conditions (OCSI Supplementary Question)
Tidsram: From enrollment to end of treatment at 9 weeks
|
Checklist of skin conditions present: burning, itching, maceration, fungal rash, folliculitis, granuloma, mechanical trauma, product sensitivity/allergy, pyoderma gangrenosum, other, none. |
From enrollment to end of treatment at 9 weeks
|
|
Peristomal skin burning severity (OCSI Supplementary Question)
Tidsram: From enrollment to end of treatment at 9 weeks
|
Rated on a numeric scale from 0 (absent) to 10 (worst burning imaginable). Assessed only if burning is reported (conditional logic from Q25). Higher scores indicate worse burning. |
From enrollment to end of treatment at 9 weeks
|
|
Peristomal skin itching severity (OCSI Supplementary Question)
Tidsram: From enrollment to end of treatment at 9 weeks
|
Rated on a numeric scale from 0 (absent) to 10 (worst itching imaginable). Assessed only if itching is reported (conditional logic from Q25). Higher scores indicate worse itching. |
From enrollment to end of treatment at 9 weeks
|
|
Time to resolution of peristomal skin complications (PSCs), assessed by the Ostomy Complication Severity Instrument (OCSI) at visits and adverse event (AE) reports between visits
Tidsram: From first PSC onset to resolution through end of treatment at 9 weeks
|
Unit of Measure: days |
From first PSC onset to resolution through end of treatment at 9 weeks
|
|
Time to recurrence of peristomal skin complications (PSCs) after resolution, assessed by the OCSI at visits and AE reports between visits
Tidsram: From PSC resolution to first recurrence through end of treatment at 9 weeks
|
Unit of Measure: days |
From PSC resolution to first recurrence through end of treatment at 9 weeks
|
|
Proportion of participants with PSC occurrence, PSC resolution, and PSC recurrence, assessed by the OCSI at visits and AE reports between visits
Tidsram: From enrollment to end of treatment at 9 weeks
|
Unit of Measure: percent (%) |
From enrollment to end of treatment at 9 weeks
|
|
Patient satisfaction with the study Seal/Ring assessed using the Study-Specific Patient Satisfaction Questionnaire (Likert scale)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied) |
From enrollment to the end of treatment at 9 weeks
|
|
Clinician Satisfaction with the study Seal/Ring assessed using the Study-Specific Clinician Satisfaction Questionnaire (Likert scale)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied) |
From enrollment to the end of treatment at 9 weeks
|
|
Ability to correctly use the seal/ring with available instructional resources, assessed by the Study-Specific Instructional Resources Question
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Single study-specific question assessing whether instructional resources (e.g., IFU, online guides) enabled correct use of the seal/ring; responses: Yes / No / Did not use instructional resources. Results will be reported as the proportion of participants in each response category. |
From enrollment to the end of treatment at 9 weeks
|
|
Seal swelling/expansion incidence, assessed by Study-Specific Swell/Expand Question
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Participant response comparing seal size at application versus at barrier change. Responses: No, seal did not swell/expand / Yes, seal swelled/expanded. |
From enrollment to the end of treatment at 9 weeks
|
|
Effectiveness of seal swelling/expansion for secure fit against leakage, assessed by Study-Specific Swell/Expand Question
Tidsram: From enrollment to end of treatment at 9 weeks
|
Participant response regarding whether swelling/expansion provided a better, more secure fit against leakage. Responses: No, not at all / Yes, somewhat / Yes, definitely (ordinal categorical). |
From enrollment to end of treatment at 9 weeks
|
|
Perceived moisture-wicking effect, assessed by the Study-Specific Moisture-Wicking Question (3-point scale)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Single study-specific question assessing perceived moisture-wicking away from peristomal skin. Responses: No, not at all / Yes, somewhat / Yes, definitely. |
From enrollment to the end of treatment at 9 weeks
|
|
Clinician agreement with the study Seal/Ring performance assessed using the Study-Specific Clinician Agreement Questionnaire (Likert scale)
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Rated on a 5-point Likert scale from 1 (Strongly agree) to 5 (Strongly disagree) |
From enrollment to the end of treatment at 9 weeks
|
|
Quantity of seals/rings, barriers, and accessories used, assessed by Study-Specific Resource Utilization Log
Tidsram: From enrollment to the end of treatment at 9 weeks
|
Unit of measure: mean/median number used per participant (counts) |
From enrollment to the end of treatment at 9 weeks
|
|
Wear/use time (longevity) of seals/rings and barriers, assessed by Study-Specific Resource Utilization Log
Tidsram: From enrollment to end of treatment at 9 weeks
|
Unit of measure: hours or days of wear time per application (time) |
From enrollment to end of treatment at 9 weeks
|
|
Peristomal skin-related unplanned healthcare visits, assessed by Study-Specific Healthcare Utilization Question
Tidsram: From enrollment to end of treatment at 9 weeks
|
Unit of measure: number of visits per participant; optionally proportion with ≥1 visit (counts/%) |
From enrollment to end of treatment at 9 weeks
|
|
Total ostomy seal/ring costs, derived from quantities recorded in the Resource and Healthcare Utilization Logs
Tidsram: From enrollment to end of treatment at 9 weeks
|
Unit of measure: currency (e.g., dollars) |
From enrollment to end of treatment at 9 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: John Whitaker, University Hospital Coventry
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 6042-OST
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .